Literature DB >> 9701199

The SstI polymorphism of the apolipoprotein C-III gene determines the insulin response to an oral-glucose-tolerance test after consumption of a diet rich in saturated fats.

J Salas1, S Jansen, J López-Miranda, J M Ordovás, P Castro, C Marín, M A Ostos, M D Bravo, J Jiménez-Perepérez, A Blanco, F López-Segura, F Pérez-Jiménez.   

Abstract

The S2 allele of the SstI polymorphism of the apolipoprotein (apo) C-III gene has been associated with elevated triacylglycerol concentrations, high blood pressure, and increased risk of coronary artery disease, all of which are characteristic of an insulin-resistant state. To study the effect of this mutation on carbohydrate metabolism in healthy persons, we gave 41 male subjects 3 consecutive diets. The first was rich in saturated fat [15% protein, 47% carbohydrate, 38% fat (20% saturated)], the second was a National Cholesterol Education Program Step 1 diet [15% protein, 57% carbohydrate, 28% fat (< 10% saturated)], and the last was rich in monounsaturated fat [15% protein, 47% carbohydrate, 38% fat (22% monounsaturated, < 10% saturated)]. At the end of each dietary period, subjects received an oral-glucose-tolerance test (OGTT). Apo C-III genotype significantly affected basal glucose concentrations (P < 0.045) and insulin concentrations after the OGTT (P < 0.012). APOC3*S1/APOC3*S2 subjects (n = 13) had higher insulin concentrations after the OGTT than APOC3*S1/APOC3*S1 subjects (n = 28) in the 3 periods (diet 1: P < 0.0004; diet 2: P < 0.01; diet 3: P < 0.008). Multiple regression analysis showed that this polymorphism predicted the insulin response to the OGTT (P < 0.031) and the difference between basal insulin concentrations and insulin concentrations after the OGTT (P < 0.002) with the saturated fat diet. In summary, our results suggest that the mutation in the apo C-III gene affects insulin response to an OGTT, which could result in reduced sensitivity to insulin, especially when persons consume diets rich in saturated fat.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9701199     DOI: 10.1093/ajcn/68.2.396

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  6 in total

1.  Haplotype analysis of Apo AI-CIII-AIV gene cluster and lipids level: Tehran Lipid and Glucose Study.

Authors:  Maryam S Daneshpour; Bita Faam; Mohamad Ali Mansournia; Mehdi Hedayati; Sohrab Halalkhor; Seyed Alireza Mesbah-Namin; Shahla Shojaei; Maryam Zarkesh; Fereidoun Azizi
Journal:  Endocrine       Date:  2011-11-22       Impact factor: 3.633

2.  Apolipoprotein A5 gene promoter region T-1131C polymorphism associates with elevated circulating triglyceride levels and confers susceptibility for development of ischemic stroke.

Authors:  Viktória Havasi; Zoltán Szolnoki; Gábor Talián; Judit Bene; Katalin Komlósi; Anita Maász; Ferenc Somogyvári; András Kondacs; Mihály Szabó; Lajos Fodor; Anita Bodor; Béla Melegh
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

3.  Apolipoprotein A5 T-1131C variant confers risk for metabolic syndrome.

Authors:  Anita Maász; Péter Kisfali; Katalin Horvatovich; Márton Mohás; Lajos Markó; Veronika Csöngei; Bernadett Faragó; Luca Járomi; Lili Magyari; Enikô Sáfrány; Csilla Sipeky; István Wittmann; Béla Melegh
Journal:  Pathol Oncol Res       Date:  2007-10-07       Impact factor: 3.201

4.  Apolipoprotein C3 SstI polymorphism in the risk assessment of CAD.

Authors:  S Chhabra; R Narang; R Lakshmy; S Vasisht; D P Agarwal; L M Srivastava; S C Manchanda; N Das
Journal:  Mol Cell Biochem       Date:  2004-04       Impact factor: 3.396

Review 5.  Genetic predictors of plasma lipid response to diet intervention.

Authors:  J M Ordovas; J R Galluzzi
Journal:  Curr Atheroscler Rep       Date:  1999-11       Impact factor: 5.967

Review 6.  Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies.

Authors:  Israa Dib; Alia Khalil; Racha Chouaib; Yolla El-Makhour; Hiba Noureddine
Journal:  Mol Biol Rep       Date:  2021-01-03       Impact factor: 2.316

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.